Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.

Stefanou MI, Palaiodimou L, Theodorou A, Safouris A, Fischer U, Kelly PJ, Dawson J, Katan M, Katsanos AH, Lambadiari V, Giannopoulos S, Alexandrov AV, Siasos G, Tsivgoulis G.Ther Adv Neurol Disord. 2024 Sep 25;17:17562864241281903. doi: 10.1177/17562864241281903. eCollection 2024.PMID: 39345822 Free PMC article. Review.